A Study on Antimicrobial Activity of Lysine-like Peptoids for the Development of New Antimicrobials

Overview

Journal Arch Microbiol

Specialty Microbiology

Date 2025 Jan 2

PMID 39745532

Authors

Jagath C Kasturiarachchi

Affiliations

Soon will be listed here.

Abstract

The development of new medicines with unique methods of antimicrobial action is desperately needed due to the emerging multidrug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus. Therefore, antimicrobial peptoids have emerged as potential new antimicrobials. Thirteen peptoid analogues have been designed and synthesized via solid phase synthesis. These peptoids have undergone a biological analysis to determine the structure-activity relationships that define their antibacterial activity. Each peptoid is composed of nine repeating N-substituted glycine monomers (9-mer). The monomer units were synthesized with three distinct alkyl side chain lengths: four-carbon butyl monomers, six-carbon hexyl monomers, and eight-carbon octyl monomers. Out of 12 different peptoids, only one peptoid called Tosyl-Octyl-Peptoid (TOP) demonstrated significant broad-spectrum bactericidal activity. TOP kills bacteria under non-dividing and dividing conditions. The Minimum Inhibitory Concentrations values of TOP for Staphylococcus epidermidis, Escherichia coli and Klebsiella were 20 µM, whereas Methicillin-resistant Staphylococcus aureus and Methicillin-sensitive Staphylococcus aureus were 40 µM. The highest MIC values were observed for Pseudomonas aeruginosa at 80 µM. The selectivity ratio was calculated, by dividing the 10% haemolysis activity (5 mM) by the median of the MIC (50 µM) yielding a selective ratio for TOP as 100. This selective ratio is well above previously reported peptidomimetics selective ratio of around 20. TOP shows broad-spectrum bactericidal action in both dividing and non-dividing bacteria in co-culture systems and intracellular bacterial killing activity. These results add new information about the antimicrobial peptoids and aid in the future design of synthetic peptoids with increased therapeutic potential.

References

Al-Ahmad A, Laird D, Zou P, Tomakidi P, Steinberg T, Lienkamp K . Nature-inspired antimicrobial polymers--assessment of their potential for biomedical applications. PLoS One. 2013; 8(9):e73812. PMC: 3767731. DOI: 10.1371/journal.pone.0073812. View

Almeida R, Matthews K, Cifrian E, Guidry A, Oliver S . Staphylococcus aureus invasion of bovine mammary epithelial cells. J Dairy Sci. 1996; 79(6):1021-6. DOI: 10.3168/jds.S0022-0302(96)76454-8. View

Arias C, Murray B . The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol. 2012; 10(4):266-78. PMC: 3621121. DOI: 10.1038/nrmicro2761. View

Bahl D, Miller D, Leviton I, Gialanella P, Wolin M, Liu W . In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and nongrowing strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1997; 41(6):1293-7. PMC: 163902. DOI: 10.1128/AAC.41.6.1293. View

Bendifallah N, Rasmussen F, Zachar V, Ebbesen P, Nielsen P, Koppelhus U . Evaluation of cell-penetrating peptides (CPPs) as vehicles for intracellular delivery of antisense peptide nucleic acid (PNA). Bioconjug Chem. 2006; 17(3):750-8. DOI: 10.1021/bc050283q. View

Bouchard D, Rault L, Berkova N, Le Loir Y, Even S . Inhibition of Staphylococcus aureus invasion into bovine mammary epithelial cells by contact with live Lactobacillus casei. Appl Environ Microbiol. 2012; 79(3):877-85. PMC: 3568545. DOI: 10.1128/AEM.03323-12. View

Brogden K . Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?. Nat Rev Microbiol. 2005; 3(3):238-50. DOI: 10.1038/nrmicro1098. View

Capitano B, Quintiliani R, Nightingale C, Nicolau D . Antibacterials for the prophylaxis and treatment of bacterial endocarditis in children. Paediatr Drugs. 2001; 3(10):703-18. DOI: 10.2165/00128072-200103100-00001. View

Chellat M, Raguz L, Riedl R . Targeting Antibiotic Resistance. Angew Chem Int Ed Engl. 2016; 55(23):6600-26. PMC: 5071768. DOI: 10.1002/anie.201506818. View

10.

Chongsiriwatana N, Patch J, Czyzewski A, Dohm M, Ivankin A, Gidalevitz D . Peptoids that mimic the structure, function, and mechanism of helical antimicrobial peptides. Proc Natl Acad Sci U S A. 2008; 105(8):2794-9. PMC: 2268539. DOI: 10.1073/pnas.0708254105. View

11.

Coates A, Hu Y, Bax R, Page C . The future challenges facing the development of new antimicrobial drugs. Nat Rev Drug Discov. 2002; 1(11):895-910. DOI: 10.1038/nrd940. View

12.

Deslouches B, Islam K, Craigo J, Paranjape S, Montelaro R, Mietzner T . Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications. Antimicrob Agents Chemother. 2005; 49(8):3208-16. PMC: 1196285. DOI: 10.1128/AAC.49.8.3208-3216.2005. View

13.

Dubois A, Midoux P, Gras D, Si-Tahar M, Brea D, Attucci S . Poly-L-Lysine compacts DNA, kills bacteria, and improves protease inhibition in cystic fibrosis sputum. Am J Respir Crit Care Med. 2013; 188(6):703-9. DOI: 10.1164/rccm.201305-0912OC. View

14.

Easton D, Nijnik A, Mayer M, Hancock R . Potential of immunomodulatory host defense peptides as novel anti-infectives. Trends Biotechnol. 2009; 27(10):582-90. PMC: 7114281. DOI: 10.1016/j.tibtech.2009.07.004. View

15.

Eltahawy A . The penetration of mammalian cells by antibiotics. J Antimicrob Chemother. 1983; 11(4):293-8. DOI: 10.1093/jac/11.4.293. View

16.

Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K . Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem. 2000; 276(8):5836-40. DOI: 10.1074/jbc.M007540200. View

17.

Gottschalk S, Ifrah D, Lerche S, Gottlieb C, Cohn M, Hiasa H . The antimicrobial lysine-peptoid hybrid LP5 inhibits DNA replication and induces the SOS response in Staphylococcus aureus. BMC Microbiol. 2013; 13:192. PMC: 3751284. DOI: 10.1186/1471-2180-13-192. View

18.

Gould I, David M, Esposito S, Garau J, Lina G, Mazzei T . New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int J Antimicrob Agents. 2011; 39(2):96-104. DOI: 10.1016/j.ijantimicag.2011.09.028. View

19.

Grave K, Torren-Edo J, MacKay D . Comparison of the sales of veterinary antibacterial agents between 10 European countries. J Antimicrob Chemother. 2010; 65(9):2037-40. DOI: 10.1093/jac/dkq247. View

20.

Gunderson C, Segall A . DNA repair, a novel antibacterial target: Holliday junction-trapping peptides induce DNA damage and chromosome segregation defects. Mol Microbiol. 2006; 59(4):1129-48. DOI: 10.1111/j.1365-2958.2005.05009.x. View